0000000000897256

AUTHOR

Daniela Righi

showing 3 related works from this author

Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study

2022

Abstract Aims The KWAY project aims to investigate the economic sustainability of the up-front NGS technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC patients. Methods The diagnostic workflow and the related sustained costs of five Italian referral centers were assessed in four different evolving scenarios were analyzed. For each scenario, two alternative testing strategies were evaluated: the Maximized Standard strategy and the Maximized NGS strategy. Results For each center, the robustness of obtained results was verified through a deterministic sensitivity analysis, observing the variation of total costs based on a variation of ±20 % of the input …

Predictive molecular pathologyLung NeoplasmsTotal costCostCost; NGS; NSCLC; Predictive molecular pathology; Single-gene test; Algorithms; High-Throughput Nucleotide Sequencing; Humans; Italy; Multicenter Studies as Topic; Carcinoma Non-Small-Cell Lung; Lung NeoplasmsNSCLCRobustness (computer science)Carcinoma Non-Small-Cell LungCost evaluationMedicineHumansMulticenter Studies as TopicNon-Small-Cell LungMolecular pathologybusiness.industryCarcinomaHigh-Throughput Nucleotide SequencingHematologyReliability engineeringWorkflowOncologyEconomic sustainabilityItalyNGSSingle-gene testNon small cellbusinessAlgorithms
researchProduct

The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients

2013

Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospective study, we evaluated the correlation between the two forms of TAM with survival time in radically resected gastric cancer patients. A total of 52 chemo- and radio- naive patients were included. Two slides were prepared for each patient and double-stained for CD68/NOS2 (M1) or CD68/CD163 (M2) and five representative high-power fields per slide were evaluated for TAM count. The median value of the two macrophage populations density and the media…

Malemedicine.medical_specialtyPathologyMultivariate analysisSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyImmune systemM1 polarization; M2 polarization; gastric cancerGastrectomyStomach NeoplasmsInternal medicinemedicineHumanstumour associated macrophages M1 polarization M2 polarization prognostic factor gastric cancerRadical surgeryprognostic factorRetrospective Studiesbusiness.industryCD68MacrophagesM2 polarizationgastric cancerM1 polarizationCell PolarityCancerRetrospective cohort studyOriginal ArticlesCell BiologyMiddle AgedPrognosisM2 Macrophagemedicine.diseaseTreatment OutcomeMultivariate Analysistumour associated macrophagesMolecular MedicineFemalebusinessCD163Journal of Cellular and Molecular Medicine
researchProduct

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

2019

No luminal; Subtipus intrínsec; Càncer de mama No luminal; Subtipo intrínseco; Cáncer de mama Non-luminal; Intrinsic subtype, Breast cancer Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estr…

0301 basic medicineCancer Researchmedicine.medical_specialtyintrinsic subtype:Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]:Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation Neoplastic [PHENOMENA AND PROCESSES]medicine.medical_treatmentEstrogen receptor:fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica [FENÓMENOS Y PROCESOS]:aminoácidos péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de estrógenos [COMPUESTOS QUÍMICOS Y DROGAS]lcsh:RC254-282Gastroenterology03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerMama - CàncerInternal medicineRegulació genèticaProgesterone receptorMedicinePAM50Original Research:neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES]Chemotherapynon-luminalbusiness.industry:Amino Acids Peptides and Proteins::Proteins::Receptors Cytoplasmic and Nuclear::Receptors Steroid::Receptors Estrogen [CHEMICALS AND DRUGS]lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyEstrògens - ReceptorsOncologyHormone receptor030220 oncology & carcinogenesisCohortgene expressionBiomarker (medicine)ImmunohistochemistrybusinessFrontiers in Oncology
researchProduct